Approximation of Long-Term Survival with Polatuzumab Vedotin Plus Bendamustine and Rituximab for Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Results Based on The GO29365 Trial

BACKGROUND: To inform healthcare professionals, payers and health technology organisations of estimated survival benefits of new treatments, statistical methods can be used to model the projected clinical benefits versus costs of new interventions. This is particularly relevant for new treatments wh...

Descripción completa

Detalles Bibliográficos
Autores principales: Felizzi, F., Launonen, Aino, Thuresson, P.-O.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2022
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9928994/
https://www.ncbi.nlm.nih.gov/pubmed/35900699
http://dx.doi.org/10.1007/s41669-022-00339-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9928994/
https://www.ncbi.nlm.nih.gov/pubmed/35900699
http://dx.doi.org/10.1007/s41669-022-00339-1

Ejemplares similares